Only semaglutide base is FDA-acceptable for compounding. Salt forms (sodium, acetate) are unapproved. Here's how to verify what API your provider uses.
About this article
Why this matters
The April 14, 2026 FDA action restricted unapproved salt forms of semaglutide (sodium, acetate). Only semaglutide base is the acceptable API. Providers using salt forms are operating outside FDA's framework.
Ask the provider directly
'What active ingredient form do you use for compounded semaglutide?' Acceptable answer: semaglutide base (USP-grade). Concerning answer: vagueness, 'proprietary,' or salt forms named.
Check the certificate of analysis
Reputable compounding pharmacies provide CoAs (Certificates of Analysis) showing potency, identification (HPLC), and purity testing. CoAs should reference the API form explicitly.
For NexLife specifically
NexLife publicly disclosed use of semaglutide base API following the April 14, 2026 FDA action. See our April 2026 FDA action analysis.